Agendia
Dutch maker of MammaPrint, the 70-gene breast cancer test validated in the MINDACT trial.
Overview
Spun out of the Netherlands Cancer Institute, Agendia developed MammaPrint (FDA-cleared 2007, the first cleared multigene prognostic test) and the BluePrint molecular subtyping assay, and sponsored MINDACT with the EORTC. It also runs the FLEX registry collecting whole-transcriptome data on MammaPrint patients.
Scorecard
All companies- modalities +2
- regions +1
- registry trials +3
Pages like this
not linked directly; found by shared links- ProductProsigna (PAM50)
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonRené Bernards
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- PairingGene-expression assay → chemotherapy omission
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- TrialTAILORx
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonCarlos Caldas
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonCharles M. Perou
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- PersonAleix Prat
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
- ProductBreast Cancer Index
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.